• Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers 

      Jansen, Iris E.; van der Lee, Sven J.; Gomez-Fonseca, Duber; de Rojas, Itziar; Dalmasso, Maria Carolina; Grenier-Boley, Benjamin; Athanasiu, Lavinia; Bahrami, Shahram; Bergh, Sverre; Djurovic, Srdjan; Fladby, Tormod; Jarholm, Jonas Alexander; Knapskog, Anne Brita; Pålhaugen, Lene; Saltvedt, Ingvild; Selbæk, Geir; Selnes, Per; Andreassen, Ole; Shadrin, Alexey; Skoog, Ingmar; Soininen, Hilkka; Tsolaki, Magda; Van Broeckhoven, Christine; Van Dongen, Jasper; van Swieten, John C.; Vandenberghe, Rik; Vidal, Jean-Sébastien; Visser, Pieter J.; Vogelgsang, Jonathan; Waern, Margda; Wagner, Michael; Wiltfang, Jens; Wittens, Mandy M.J.; Zetterberg, Henrik; Zulaica, Miren; van Duijn, Cornelia M.; Bjerke, Maria; Engelborghs, Sebastiaan; Jessen, Frank; Teunissen, Charlotte E.; Pastor, Pau; Hiltunen, Mikko; Ingelsson, Martin; Clarimón, Jordi; Sleegers, Kristel; Ruiz, Agustín; Ramirez, Alfredo; Cruchaga, Carlos; Lambert, Jean-Charles; van der Flier, Wiesje M. (Journal article; Peer reviewed, 2022)
      Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European ...